Background: The goal of this study was to identify target areas for psychosocial intervention for depressed patients with early inflammatory arthritis.
Methods: One hundred and sixty-five patients with early inflammatory arthritis (> or =1 joint with synovitis for > or =6 weeks and <1 year with a diagnosis of either rheumatoid or undifferentiated inflammatory arthritis) were referred to the McGill Early Arthritis Registry (McEAR) by their rheumatologist. McEAR patients agree to periodic physical exams and to completing questionnaires. Demographic, disease and psychosocial factors were compared between patients screening positive and negative for depression using independent samples t tests and Pearson's chi(2) test and then were entered into a logistic regression model examining the likelihood of screening positive for depression.
Results: Thirty-eight (23%) patients screened positive for depressive symptoms. Patients with symptoms of depression had significantly worse disease severity, disability, and pain, engaged in more emotional preoccupation coping, had less self-efficacy for pain and other arthritis-related symptoms, smaller social networks and were less satisfied with social support than the nondepressed group. In logistic regression analyses, pain and emotional preoccupation coping were positively related to the likelihood of screening positive for depression, while satisfaction with social support was negatively related to the likelihood of screening positive for depression
Conclusion: Higher pain levels, emotional preoccupation coping and dissatisfaction with social support were related to depressive symptoms in this study. This suggests that the optimal care of depressed patients with inflammatory arthritis would include a psychosocial approach that addresses these specific target areas.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000142522 | DOI Listing |
Curr Rheumatol Rep
January 2025
Rheumatologisches Versorgungszentrum Steglitz, Ruhr Universität Bochum, Schloßstr.110, 12163, Berlin, Germany.
Purpose Of Review: Axial spondyloarthritis (axSpA) is a rather prevalent chronic inflammatory rheumatic disease that affects already relatively young patients. It has been known better since the end of the nineteenth century but quite a lot has been learned since the early 60ies when the first classification (diagnostic) criteria for ankylosing spondylitis (AS) were agreed on. I have been part of many developments in the last 30 years, and I'm happy to have been able to contribute to the scientific progress in terms of diagnosis, imaging, pathophysiology and therapy.
View Article and Find Full Text PDFCurr Opin Oncol
January 2025
Gustave Roussy Departement Interdisciplinaire de Soins de Support aux Patients en Onco-hematologie, Villejuif, France.
Purpose Of Review: Immune checkpoint inhibitors (ICI) have become an integral part of oncology treatment. ICI currently has approval for more than thirty tumor types with proven efficacy. However, ICI can expose patients to inflammatory side effects, such as immuno-related adverse events (irAE).
View Article and Find Full Text PDFJ Periodontal Res
January 2025
Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Turin, Italy.
Aim: To test a BiO-Optimizing Site Targeted (BOOST) approach to periodontal regeneration by the adjunctive use of locally delivered doxycycline (DOX) 2 weeks prior to minimally invasive surgery in terms of clinical and radiographic outcomes at 1 year.
Methods: For this randomized clinical trial, stage III/IV periodontitis patients presenting sites with intrabony defects and bleeding on probing (BoP+) after steps 1-2 of periodontal treatment were included. Sites were treated via subgingival instrumentation with or without a BOOST approach by local DOX.
Unlabelled: X-linked Lymphoproliferative Syndromes (XLP), which arise from mutations in the or genes, are characterized by the inability to control Epstein-Barr Virus (EBV) infection. While primary EBV infection triggers severe diseases in each, lymphomas occur at high rates with XLP-1 but not with XLP-2. Why XLP-2 patients are apparently protected from EBV-driven lymphomagenesis, in contrast to all other described congenital conditions that result in heightened susceptibility to EBV, remains a key open question.
View Article and Find Full Text PDFHuman Kv1.3, encoded by , is expressed in neuronal and immune cells. Its impaired expression or function produces chronic inflammatory disease and autoimmune disorders, the severity of which correlates with Kv1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!